Deadline
Passed
Lead Plaintiff Deadline: April 18, 2022
(1) the investigational device exemption study evaluating the use of the Company’s CellFX System to treat sebaceous hyperplasia lesions failed to meet its primary endpoints; (2) as a result, there was a substantial risk that the U.S. Food and Drug Administration would reject Pulse’s 510(k) submission seeking to expand the label for the CellFX System to treat sebaceous hyperplasia lesions; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.